| Literature DB >> 22331137 |
H D C Francescato1, J R A Chierice, E C S Marin, F Q Cunha, R S Costa, C G A Silva, T M Coimbra.
Abstract
Animal models of gentamicin nephrotoxicity present acute tubular necrosis associated with inflammation, which can contribute to intensify the renal damage. Hydrogen sulfide (H2S) is a signaling molecule involved in inflammation. We evaluated the effect of DL-propargylglycine (PAG), an inhibitor of endogenous H2S formation, on the renal damage induced by gentamicin. Male Wistar rats (N = 8) were injected with 40 mg/kg gentamicin (im) twice a day for 9 days, some of them also received PAG (N = 8, 10 mg·kg-1·day-1, ip). Control rats (N = 6) were treated with saline or PAG only (N = 4). Twenty-four-hour urine samples were collected one day after the end of these treatments, blood samples were collected, the animals were sacrificed, and the kidneys were removed for quantification of H2S formation and histological and immunohistochemical studies. Gentamicin-treated rats presented higher sodium and potassium fractional excretion, increased plasma creatinine [4.06 (3.00; 5.87) mg%] and urea levels, a greater number of macrophages/monocytes, and a higher score for tubular interstitial lesions [3.50 (3.00; 4.00)] in the renal cortex. These changes were associated with increased H2S formation in the kidneys from gentamicin-treated rats (230.60 ± 38.62 µg·mg protein-1·h-1) compared to control (21.12 ± 1.63) and PAG (11.44 ± 3.08). Treatment with PAG reduced this increase (171.60 ± 18.34), the disturbances in plasma creatinine levels [2.20 (1.92; 4.60) mg%], macrophage infiltration, and score for tubular interstitial lesions [2.00 (2.00; 3.00)]. However, PAG did not interfere with the increase in fractional sodium excretion provoked by gentamicin. The protective effect of PAG on gentamicin nephrotoxicity was related, at least in part, to decreased H2S formation.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22331137 PMCID: PMC3854203 DOI: 10.1590/s0100-879x2012007500016
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Parameters of renal function of saline-, PAG-, gentamicin-, and gentamicin+PAG-treated rats 2 days after the end of the treatment.
| Saline (N = 6) | PAG (N = 4) | Gentamicin (N = 8) | Gentamicin+PAG (N = 8) | |
|---|---|---|---|---|
| Pcreat (mg/mL) | 0.49 (0.21; 0.61) | 0.48 (0.46; 0.51) | 4.06* (3.00; 5.87) | 2.20 (1.92; 4.60) |
| BUN (mg/mL) | 43.38 (34.10; 48.80) | 46.30 (41.70; 56.10) | 510.10* (400.80; 637.40) | 263.80#* (206.60; 476.20) |
| FENa+ (%) | 0.42 (0.32; 0.66) | 0.66 (0.49; 0.70) | 9.63* (7.34; 16.61) | 8.60* (6.71; 20.87) |
| FEK+ (%) | 44.37 (38.81; 52.80) | 41.87 (36.96; 43.41) | 181.10* (252.50; 234.40) | 150.20 (136.70; 217.30) |
Saline (0.15 M NaCl, im) and gentamicin (40 mg/kg, im) were injected twice a day for 9 days. PAG (10 mg·kg−1·day−1, ip) was injected for 9 days starting on day one of gentamicin treatment and the injections were performed 4 h after the first daily injection of gentamicin and 4 h before the second. PAG = DL-propargylglycine; Pcreat = plasma creatinine; BUN = blood urea nitrogen; FE = fractional excretion. Data are reported as median and interquartile ranges (25-75% percentile). *P < 0.01 compared to saline; #P < 0.05 compared to gentamicin (Kruskal-Wallis test followed by the Dunn post-test).
Figure 1.Masson's trichrome-stained histological sections (A and B) and immunolocalization of vimentin (C and D) and ED1+ cells (macrophages/monocytes; E and F) from the renal cortex of rats treated with gentamicin (A, C, E) or gentamicin+PAG (B, D, F), 2 days after the end of the treatment. Note the presence of tubular necrosis (black arrow) and the increase of relative interstitial area in A (asterisk). This alteration was less intense in B. Vimentin expression (white arrows) and the number of ED1+ cells (dotted arrows) were higher in C and E than in D and F. Magnification bars = 20 µm.
Score for tubulointerstitial lesions (TIL), vimentin and number of ED1+ cells (macrophages/monocytes) in the renal cortex of saline-, PAG-, gentamicin-, and gentamicin+PAG-treated rats two days after the end of treatment.
| Saline (N = 6) | PAG (N = 4) | Gentamicin (N = 8) | Gentamicin+PAG (N = 8) | |
|---|---|---|---|---|
| TIL | 0 | 0 | 3.50* (3.00; 4.00) | 2.00#* (2.00; 3.00) |
| Vimentin | 0.10 (0.06; 0.12) | 0.13 (0.004; 0.200) | 2.89* (2.84; 3.43) | 1.84#* (1.69; 2.42) |
| ED1+ cells | 4.94 ± 0.61 | 6.66 ± 0.41 | 154.30* ± 7.67 | 90.29#* ± 8.68 |
Data are reported as median and interquartile range (25-75% percentile) for TIL and vimentin (data compared by the Kruskal-Wallis test followed by the Dunn post-test) or mean ± SEM for ED1+ cells (data compared using analysis of variance with the multiple comparisons Newman-Keuls test). Drug treatments are given in the legend to Table 1. PAG = DL-propargylglycine. *P < 0.01 compared to saline; #P < 0.01 compared to gentamicin.